Clinical trial · Observational
Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer
NIS Xeloda in Gastric Cancer
NCT02274376CI-TRIAL-00024672completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- Up to 4 years
- measure
- Safety and tolerability: incidence and nature of adverse drug reactions
- timeFrame
- Up to 4 years
Secondary outcomes (4)
- measure
- Proportion of patients with modifications in Xeloda dosing
- timeFrame
- Up to 4 years
- measure
- Average duration of treatment
- timeFrame
- Up to 4 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged \>/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (first-line chemotherapy) * Informed consent Exclusion Criteria: * Contraindications to Xeloda per the Summary of Product Characteristics (SmPC)
References
Publications (0)
Data not yet available
No reference posted for this study.